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Distinct neurometabolic proﬁles are evident in the
anterior cingulate of young people with major
psychiatric disorders
DF Hermens*, J Lagopoulos, SL Naismith, J Tobias-Webb and IB Hickie
Currently, there are no validated neurobiological methods for distinguishing different pathophysiological pathways in young
patients presenting in the early phases of major psychiatric disorders. Hence, treatments are delivered simply on the basis of
their possible effects on nonspeciﬁc symptom constructs such as depression, cognitive change or psychotic symptoms. In this
study, the ratios (relative to creatine) of key metabolites (N-acetyl aspartate, myoinositol, glutamate and glutathione) were
measured with proton magnetic resonance spectroscopy (
1H-MRS) within the anterior cingulate cortex of 88 young persons
presenting with major mood or psychotic symptoms. We derived empirically (using a cluster analytical technique) three
subgroups ofsubjects on the basis oftheir patternsofinvivobrain biochemistry. The threesubgroupswere distinguished(from
each other) by all the four metabolites, in particular, glutathione and glutamate. By contrast, the groups could not be
distinguishedbydifferences intermsof otherdemographic, functionalorclinicalmeasures. We proposethatthis
1H-MRS-based
subclassiﬁcation system could be used as the basis for much more speciﬁc tests of novel intervention strategies (notably,
antioxidant and glutamatergic therapies) early in the course of major psychiatric disorders.
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Introduction
The failure to identify clear neurobiological markers of the
pathophysiological pathways underpinning the severe mood
or psychotic disorders remains a major limitation in clinical
psychiatry. Currently-used diagnostic categories map poorly
onto proposed risk factors or persistent pathophysiology. An
alternative clinical strategy has been to focus attention more
speciﬁcally on those in the earliest active phases of the major
mood and psychotic disorders.
1 However, young persons
(typically 15–25 years) presenting to care close to the onset
of illness typically report admixtures of anxiety, depressive,
hypomanic or psychotic symptoms.
2 Although clearly dis-
abled by these symptoms,
3 they do not ﬁt readily into current
diagnostic categories.
The development of a clinical staging model to categorize
these various early phases of illness is useful for testing the
beneﬁts of a variety of intervention strategies.
1,4,5 However,
the real utility of these promising ‘pre-emptive’
6 or ‘early
intervention’
7 strategies may well depend on our capacity to
identify genuine neurobiological markers of active pathophy-
siologyduringtheseearlyactivephasesofillness.Ratherthan
assuming that current diagnostic systems relate to speciﬁc
developmental or current pathophysiologies, we propose that
group membership based on direct measures of brain
structure or function may prove to be a more valid approach.
8
In this study, we explore the capacity of four key markers to
create novel groupings based on various biochemical
measures derived by magnetic resonance spectroscopy
(MRS). The four markers are: (i) N-acetyl aspartate (NAA),
avalidatedmarkerofneuronaldensityandviability
9,10(NAAis
an amino acid thought to be present entirely within neurons
and axons but absent in glial cells.) (ii) myoinositol (MI), which
is purported to be only present in glial cells (speciﬁcally the
astrocytes) and assuch increased concentrations are thought
to reﬂect glial activation;
11 (iii) glutamate (GLU), which is the
most abundant excitatory neurotransmitter (precise informa-
tion processing is dependent on fast and efﬁcient removal of
glutamate from the synaptic cleft.);
12 and (iv) glutathione
(GSH), which is a predominant intracellular antioxidant,
principally involved in neutralizing reactive oxygen species
generated within the brain.
Proton magnetic resonance spectroscopy (
1H-MRS) has
already produced a number of important insights into the
neurobiology of a range of psychiatric conditions. Many of
these studies have focused on (or included) the anterior
cingulatecortex(ACC), astructurethathasbeenimplicatedin
the pathophysiology of several psychiatric disorders, includ-
ing bipolardisorder,
13depression
14,15andschizophrenia.
16,17
The ACC is critically involved in performance monitoring and
cognitive control and has a key role in emotional and social
behavior.
18 The ACC comprises a dorsal (cognitive) division
and a rostral–ventral (affective) division. The dorsal sub-
division has been associated with modulation of attention
to inﬂuence sensory or response selection, complex motor
control and motivation. The rostral–ventral subdivision is
Received 27 September 2011; revised 15 March 2012; accepted 5 April 2012
Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, Camperdown, New South Wales, Australia
*Correspondence: Dr DF Hermens, Clinical Research Unit, Brain and Mind Research Institute, University of Sydney, 100 Mallet Street, Camperdown, NSW 2050, Australia.
E-mail: daniel.hermens@sydney.edu.au
Keywords: anterior cingulate; glutamate; glutathione; psychiatric; spectroscopy; youth
Citation: Transl Psychiatry (2012) 2, e110, doi:10.1038/tp.2012.35
& 2012 Macmillan Publishers Limited All rights reserved 2158-3188/12
www.nature.com/tpthought to be primarily involved in assessing the salience of
emotional and motivational information and the regulation of
emotional responses.
Although there have been a signiﬁcant number of studies of
these markers, individually across a range of psychiatric
disorders,fewstudieshaveassessedNAA,MIandGLUinthe
same individuals and none of the studies have included all
four spectroscopic markers (including GSH). Although there
are methodological differences, there appears to be little con-
sistency within each diagnostic category, suggesting that other
factors may be better matched with underlying brain changes.
Empirically-based approaches to subject grouping are not
often employed in clinical psychiatry. In our view, such data-
driven approaches may identify putative biomarkers that, with
furtherexperimentalcharacterization,maydescribeorexplain
illness trajectories beyond (or in spite of) diagnostic pheno-
type. Such neurobiological markers may also be more
predictive of disability, functional status, cognitive impairment
or response to speciﬁc treatments. Cluster analysis is a
classiﬁcation technique for forming homogeneous groups
within complex data sets.
19 Ideally, a good cluster solution is
obtained when the data segregate into theoretically mean-
ingful subsets;
20 in this sense, cluster analysis can be used
as a hypothesis-generating technique.
21 In this study, we
performed a cluster analysis utilizing four key neurometabo-
lites (ie NAA, MI, GLU and GSH) measured within the ACC in
a large sample of young (16–30years old), health-seeking
psychiatric outpatients.
Materials and methods
Eighty eight outpatients aged 16–30 years were recruited
from specialized referral services for the assessment and
early intervention of mental health problems in young
people.
22 Patients were assessed bya psychiatrist, according
to DSM-IV criteria, who also made a primary diagnosis of an
axis I psychiatric disorder (ie depressive disorder (n¼37),
bipolar disorder (n¼29) or psychotic disorder (n¼22)).
23 All
patients were receiving clinician-based case management
and relevant psychosocial interventions at the time of
assessment. Additionally, patients who were treated with
psychotropic medications were assessed under ‘treatment as
usual’ conditions, whereby their normal medications were not
altered. At the time of assessment, 12% of the patients were
not taking any psychotropic medications; 53% were taking a
second-generation anti-depressant; 53% were taking an
atypical antipsychotic medication; and 23% were taking a
mood stabilizer. Of those medicated, 54% were taking more
thanoneofthesepsychotropicmedications;forthemajorityof
these patients (44% of those medicated) this polytherapy
included an antidepressant.
The healthy control group (n¼25) was recruited from the
community via advertisements. Exclusion criteria for all
participants were medical instability (as determined by the
treating psychiatrist), history of neurological disease (eg
tumour, head trauma, epilepsy), medical illness known to
impact cognitive and brain function (eg cancer, ECT in last
3 months), intellectual and/or developmental disability
(a predicted IQ score o70), insufﬁcient English for testing or
psychiatric assessment and current substance dependence.
Participants were asked to abstain from drug and alcohol
use for 48h before testing. The study was approved by the
University of Sydney Human Research Ethics Committee and
all participants gave written informed consent.
Clinical assessment. An independent psychiatrist or
trained research psychologist conducted a structured
clinical interview to determine the nature and history of any
mental health problems. This interview served as a means to
screen control subjects for past psychiatric disorders and
current symptoms. The interview included the Hamilton
Depression Rating Scale (17-item)
24 to quantify current
mood symptoms; the Brief Psychiatric Rating Scale
25 to
quantify general psychiatric symptoms at the time of
assessment; and the Social and Occupational Functioning
Assessment Scale,
26 where a participant’s functioning is
rated from 0 to 100, with lower scores suggesting more
severe impairment. All participants were also asked to
complete the Kessler-10,
27 which is a brief self-report
instrument designed to detect psychological distress and
affective caseness.
28 As a proxy measure for duration of
illness, the age at which each patient ﬁrst engaged a mental
health service was recorded.
1H-MRS data acquisition.
1H-MRS data were acquired
using a 3-T GE Discovery MR750 MRI scanner (GE Medical
Systems, Milwaukee, WI, USA), using an 8-channel-phased
array head coil. The protocol comprised of a three-dimen-
sional sagittal whole-brain scout for orientation and posi-
tioning of all subsequent scans (TR¼50ms; TE¼4ms;
256matrix; no averaging, z¼5mm thickness). To aid in the
anatomical localization of sampled voxels, a T1-weighted
Magnetization Prepared RApid Gradient-Echo (MPRAGE)
sequence producing 196 sagittal slices (TR¼7.2m;
TE¼2.8m; ﬂip angle¼101; matrix 256 256; 0.9mm
isotropic voxels) was also acquired. Finally, single voxel
1H-MRS using a Point RESolved Spectroscopy (PRESS)
acquisition with two chemical shift-selective imaging pulses
for water suppression was acquired from a voxel placed
midline in the ACC, with the following parameters: TE¼35m,
TR¼2000m, 128 averages voxel size 2 2 2cm. Anato-
mical localization of voxel placement was based on the
Talaraich brain atlas
29 and positioning was guided by the
T1 MPRAGE image as shown in Figure 1. All spectra
were shimmed (using automatic and manual higher-order
shimming) to achieve full-width half maximum of o13Hz.
Before any postprocessing, all spectra were visually
inspected, separately by two independent raters, to ensure
the consistency of the data. Poorly ﬁtted metabolite peaks as
reﬂected by large Cramer–Rao Lower Bounds (CRLB) were
excluded from further analysis. Subjects’ data was included
in this study if the CRLB was less than 20%.
1H-MRS spectrum analysis. Spectra were quantiﬁed with
the LCModel software package
30 using a PRESS TE¼35
basis set of 15 metabolites (included NAA, GLU, MI and
GSH) and incorporating macromolecule and baseline ﬁtting
routines. The coordinates of the ACC voxels were deter-
mined in the SAGE (Spectroscopy Analysis GE) software
package and the reconstructed acquisition voxels were then
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Translational Psychiatrycorrected for gray-matter content. For segmentation,
individual structural images used for voxel placement were
segmented into gray matter, white matter and CSF using the
FAST4 algorithm as implemented in FSL.
31 To determine the
sensitivity of the acquisition technique and validate the GSH
ﬁndings reported in this manuscript, we also undertook an
in vitro phantom experiment. Varying physiological concen-
trations of GSH (0–7.0mM) were mixed together with
creatine, glutamate, glutamine and phosphate (which were
all present in physiological brain concentrations), and the
linear dependence of GSH was calculated to be R
2¼0.994
(see Figure 2). Statistical analyses were then conducted on
the following gray matter-corrected metabolites, NAA, MI,
GLU and GSH. All subsequent metabolite levels were
reported as ratios over creatine.
Statistical analyses. Statistical analyses were performed
using SPSS for Windows 20.0. Values of the four MRS
variables (NAA/Cr, MI/Cr, GLU/Cr, GSH/Cr), which were
standardized across the sample of patients, so that they
could be compared with each other. A hierarchical cluster
analyses utilizing Wards method of minimum variance with a
squared Euclidean distance measure was conducted to
identify spectroscopic proﬁles. The cluster analysis
technique was based on our previous neuropsychological
study
8 and statistical recommendations.
32
One-way between-subject analyses of variance (ANOVA)
were used to assess the differences in demographic,
functional and clinical variables among cluster groups.
The w
2 test was used to compare the ratio of females to
males across cluster groups. Signiﬁcance levels were set at
Po0.05. Effect sizes were calculated (d¼mean difference/
mean s.d.) to evaluate pair-wise group comparisons (where
d40.8 was considered to be of large effect size).
A conﬁrmatory (standard) discriminant function analysis
(DFA) was performed to determine which spectroscopic
variables best distinguished the cluster groups.
Results
Cluster characteristics. Agglomeration coefﬁcients gene-
rated by cluster analysis revealed a demarcation point
between three- and four-cluster solutions, suggesting that a
three-cluster solution best distinguished all the cases, which
was subsequently conﬁrmed by inspection of the dendrogram.
The resultant clustering revealed three relatively well-sized
groups (cluster 1: n¼20; cluster 2: n¼28; cluster 3: n¼29),
indicating that the appropriate number of clusters was selected.
It should be noted that 11 cases were not included in the ﬁnal
analysis; 9 cases were excluded owing to CRLB scores,
exceeding 20% for at least one spectroscopic variable, and
Figure 1 Left panel: Sagittal views of representative T1-weighted images illustrating the voxel placement for the anterior cingulate (white box). Right panel: Water-
suppressedspectra(sampledfromtheanteriorcingulate)processedusingLCModelfromasinglerepresentativesubject.:GLU,glutamate;GSH,glutathione;MI,myoinositol;
NAA, N-acetylaspartate.
r2 = 0.99391
0
2
4
6
8
10
12
14
16
18
L
C
M
o
d
e
l
 
[
G
S
H
]
Actual [GSH] (mM)
8 7 6 5 4 3 2 1 0
Figure 2 Results from an in vitro phantom study used to validate the GSH
spectroscopy ﬁndings.
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Translational Psychiatrythe remaining 2 because gray matter segmentation could not
be performed owing to excessive movement or poor gray–
white matter differentiation in the structural image. The
resultant spectroscopic proﬁles for the three cluster groups
are depicted in Figure 3. ANOVA determined signiﬁcant
(all Po0.01) main effects of cluster group for three of the four
spectroscopic variables. As indicated in Figure 3, the largest
effect sizes were evident for NAA/Cr (between clusters 1 and
3; d¼2.2) and GLU/Cr (between clusters 1 and 3; d¼2.1).
Across all the four variables, the smallest difference observed
was for MI/Cr levels between cluster 1 and cluster 3 (d¼0.3).
The three cluster groups were compared in terms of
demographic, functional and clinical variables (see Table 1).
According to w
2 analysis, the clusters do not differ signi-
ﬁcantly in the distribution of each gender. ANOVAs for the
subsequent variables revealed no main effects of cluster
group for any of the remaining demographic, functional
or clinical variables. Similarly, the three cluster groups did
not differ signiﬁcantly (according to w
2 tests) with respect
to the distribution of primary diagnoses or type of medication
(see Table 2).
Discriminant function analysis. With the four spectro-
scopic variables entered (simultaneously) as predictors, DFA
conﬁrmed the distinct neurometabolite proﬁles by generating
two functions to separate the 3 cluster groups. The ﬁrst
function accounted for 60% of the differences among the
clusters (Wilk’s l¼0.191, Po0.001). The second function
explained the remaining variance (40%) and was also statis-
tically signiﬁcant (Wilk’s l¼0.490, Po0.001). The structure
matrix showed a clear delineation, with function-1 being
characterized by a high discriminant loading for GLU/Cr
(r¼0.716) and MI/Cr (r¼ 0.803), whereas function-2 was
characterized by GSH/Cr (r¼ 0.753).
Comparison with healthy controls. As a secondary
analysis, we sought to determine whether there were any
potential abnormalities in the spectroscopic variables of each
-1.5
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Figure 3 Proﬁle of standardized scores (with s.e. bars) for ACC-derived spectroscopic (neurometabolite) variables by cluster group. Cr, creatine; GLU, glutamate; GSH,
glutathione; MI, myoinositol; NAA, N-acetylaspartate.
Table 1 Mean scores (±s.d.) for demographic and clinical variables across clusters; between group differences were tested by w
2 or ANOVA
Cluster 1
(N¼20)
Cluster 2
(N¼28)
Cluster 3
(N¼29)
Signiﬁcance
test (P)
Effect sizes, d Controls
(N¼25)
1v s2 1v s3 2v s3
Sex (f/m) 11/9 16/12 15/14 w
2 (2, 77)¼0.2 (0.918) n.a. n.a. n.a. 11/14
Age, years 22.0±3.6 22.2±3.7 22.8±4.0 F (2, 76)¼0.3 (0.745) 0.1 0.2 0.1 23.0±2.6
Predicted IQ 104.5±6.8 106.3±7.6 103.8±7.7 F (2, 73)¼0.8 (0.454) 0.2 0.1 0.3 104.8±8.2
Education, years 12.9±2.0 13.8±2.4 13.8±2.2 F (2, 76)¼1.3 (0.280) 0.4 0.4 0.0 14.6±1.8
SOFAS 61.7±10.7 62.9±11.8 62.9±14.0 F (2, 73)¼0.1 (0.936) 0.1 0.1 0.0 91.0±2.5
K-10 total 29.7±8.7 23.9±8.0 25.2±8.4 F (2, 73)¼2.7 (.070) 0.7 0.5 0.2 15.4±6.8
HDRS total 15.3±8.1 11.1±6.7 10.9±7.5 F (2, 75)¼2.4 (0.101) 0.6 0.5 0.0 1.7±2.2
BPRS total 42.1±8.5 39.9±8.9 39.5±9.2 F (2, 74)¼0.5 (0.588) 0.2 0.3 0.0 26.8±3.3
Abbreviations: ANOVA, analysis of variance; BPRS, Brief Psychiatric Rating Scale; f, female; HDRS, Hamilton Depression Rating Scale; K-10, Kessler-10; m, male;
SOFAS, Social and Occupational Functioning Assessment Scale.
Effect sizes (d) for each pair-wise cluster comparison are also provided.
wdenote large effect sizes (d40.8). Scores for the control group are also provided.
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Translational Psychiatrycluster group as compared with those of healthy controls.
Twenty-ﬁve controls (aged 18–28 years) were selected
consecutively with the goal of achieving a similar gender
ratio (56% females) as the patient group (54% female).
Omnibus ANOVA showed that the controls did not
signiﬁcantly differ from the three cluster groups in terms
of age (F (3, 101)¼0.421, P¼0.739), years of education
(F (3, 101)¼2.491, P¼0.065) or predicted IQ (F (3, 93)¼
0.511, P¼0.676). Post hoc Dunnett’s tests revealed only
one signiﬁcant difference (Po0.05) between any of the
cluster groups and controls; cluster 1 had fewer (12.9±2.1)
years of education compared with the controls (14.6±1.8
years).
The GM-corrected concentration scores for each metabo-
lite/creatine across each cluster group were compared with
controls (see Figure 4) and Dunnett’s tests revealed the
following: (i) cluster 1 had signiﬁcantly (Po0.001) higher
levels of NAA/Cr and GLU/Cr; (ii) cluster 2 had signiﬁcantly
lower levels of MI/Cr (Po0.05) but higher levels of GSH/Cr
(Po0.01) and (ii) cluster 3 had signiﬁcantly higher levels of
MI/Cr compared with controls.
Discussion
This study proposes that three distinct subgroups of young
patients presenting with admixtures of depressive and
psychotic symptoms can be identiﬁed on the basis of
1H-
MRS-derived ACC neurometabolite proﬁles. Notably, mem-
bership of these subgroups did not reﬂect other demographic
or clinical features (for example, age, sex ratio, education,
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Figure 4 Gray-matter-corrected neurometabolite (clockwise from top left panel: NAA; MI; GLU; GSH) ratio to creatine (with standard error bars) for each cluster group
versus controls.
Table 2 Cross-tabulation of cluster-group by (a) primary diagnosis (top panel)
and (b) type of current medication (bottom panel)
Cluster 1
(N¼20)
Cluster 2
(N¼28)
Cluster 3
(N¼29)
(a) Primary diagnosis
Depression
Count 10 10 15
% 50.0% 35.7% 51.7%
Bipolar
Count 5 7 9
% 25.0% 25.0% 31.0%
Psychosis
Count 5 11 5
% 25.0% 39.3% 17.2%
(b) Current medication
NIL
Count 2 3 4
% 10.0% 10.7% 3.8%
Any antidepressant
Count 15 14 17
% 75.0% 50.0% 58.6%
Any antipsychotic
Count 11 18 15
% 55.0% 64% 51.7%
Any mood stabilizer
Count 2 7 8
% 10.0% 25.0% 27.6%
w
2 for (i) cluster group by primary diagnosis (w
2(4, 77)¼3.8, P¼0.440);
(ii) cluster group by ‘any antidepressant’ (w
2(2, 77)¼3.2, P¼0.201); (ii) cluster
group by ‘any antipsychotic’ (w
2(2, 77)¼1.0, P¼0.616); (ii) cluster group by
‘any mood stabiliser’ (w
2(2, 77)¼2.3, P¼0.309).
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distribution of primary diagnoses and current medication).
Three subgroup proﬁles were identiﬁed. Cluster 1, repre-
senting 26% of the cases, was characterized by increased
levels of both NAA/Cr and GLU/Cr. This pattern of ﬁndings
may represent a relationship between failed neuronal pruning
(represented by increased NAA) and a consequent hyper-
functioning of (the glutamatergic) N-methyl-D-aspartate
receptor (NMDAr) system.
33 Cluster 2 (36% of the sample)
was characterized by high levels of GSH/Cr and low levels of
MI/Cr. Elevated GSH signiﬁes an increased capacity for the
removal of reactive oxygen species most often due to
increasedaccumulationofthesefreeradicals.Takentogether
with decreased levels of MI, which is predominantly contained
withinthe astrocyte,this maybereﬂective ofmechanismsthat
underpin an oxidative stress reaction that may include the
collateral elimination of glia. Cluster 3 (38% of the sample)
was characterized by low levels of NAA/Cr, GLU/Cr and GSH/
Cr suggestive of disruptions in GLU synthesis and neuro-
transmission. The observed reduction in GLU may also, in
part, account for the reduced GSH, as GLU (along with
cysteine and glycine) is a precursor of GSH synthesis.
Aberrations in the bioavailability of GLU may ultimately result
in a decrease in the brain’s capacity to effectively neutralize
reactive oxygen species via oxidative stress mechanisms.
Our ﬁndings suggest that there may be an association
between NAA/Cr and GLU/Cr across the cluster groups, as
evidenced by cluster 1 showing the highest levels of both
metabolites, whereas cluster 3 showed the lowest levels of
each. To our knowledge, few studies have demonstrated an
association between in vivo NAA and GLU levels in
psychiatric cohorts. A recent study
34 has shown a strong
correlation between absolute NAA and GLU concentrations in
the hippocampus of older patients with stable bipolar disorder
and although the GLU levels were signiﬁcantly increased
(compared with controls), their NAA levels were apparently
normal. Numerous studies have shown that within the ACC,
NAA is signiﬁcantly decreased in patients with psycho-
sis,
17,35–37 bipolar disorder
38,39 and depression.
40–43 How-
ever, the stage of illness may assume an important role with
evidence of increased ACC-NAA in adolescents with bipolar
disorder
44 as well as in young adults with ﬁrst-episode
depression.
42 There are also reports of no differences in
ACC-NAA between ultra-high risk and ﬁrst-episode psychosis
individuals and healthy controls.
45
Similarly, there are mixed ﬁndings with respect to ACC–
GLU across various patient groups at various stages of
illness; this particular literature has been made even more
complicated by the use of various
1H-MRS indices of in vivo
GLUlevels. Arecentmeta-analysis
46concludedthatalthough
ACC-GLU is reduced in major depression, it may be state-
dependent. Similarly, decreased ACC–GLU has been
reported in schizophrenia.
47,48 However, there are also null
ﬁndings for psychosis,
49 bipolar disorder
50 and depression
51
aswell as separate evidence of increased ACC–GLU levels in
bipolar disorder
13,52 and psychosis.
49 A recent review
53 has
suggested that GLU may distinguish depressive from manic
episodes, with reduced levels consistent with the former and
increased levels consistent with the latter. Our ﬁndings do not
support this supposition, but there are subgroups of patients
that differ in neurochemical proﬁles, and not necessarily their
symptomatology or diagnosis.
Only one cluster group was distinguished by their levels of
MI; although the remaining cluster groups showed normal
levels, cluster 2 showed signiﬁcantly decreased MI levels as
compared with controls. Although decreased MI level has
been shown within the ACC of those with major depres-
sion
43,54 and schizophrenia,
48 there have been reports of null
ﬁndings in bipolar disorder
55 and depression
56 as well as
increased levels of ACC-MI in bipolar disorder.
52
Interestingly, the least studied of these four metabolites,
GSH, was strongly loaded onto the second DFA-determined
function, which accounted for 40% of the variance between
the clusters. Furthermore, as indicated in Figure 3, GSH
appearstobethemetabolitethatmostclearlydistinguishesall
three of the cluster groups. There are few studies that have
assessed the GSH levels directly in relevant patient samples.
Do et al.
57 reported a signiﬁcant decrease (B50%) of GSH
withintheprefrontalcortexofschizophreniform/schizophrenia
patients. Matsuzawa et al.
58 found no differences in GSH
levels within the posterior medial frontal cortex of schizo-
phrenic patients as compared with controls. By contrast,
Wood et al.
59 reported that GSH levels were increased in the
medial temporal lobes of ﬁrst-episode psychosis (FEP)
patients. The latter authors attributed their reverse ﬁndings
for GSH to the earlier clinical phase of their patients (that is
compared with studies of older patients with chronic schizo-
phrenia). This suggests that early in illness, at least for a
subset of FEP patients, as there may be an oxidative stress
reaction, a compensatory response is mounted (character-
ized by a surge in GSH).
Membership of these groups (according to this study) could
now be used as the basis for stratifying future clinical trials of
the efﬁcacy of either novel (for example, omega-3 fatty acids,
antioxidanttherapies,glutamatergicagents)orotherstandard
treatments (for example, antidepressants, Lithium, anti-
convulsants, antipsychotics). Further, the importance of the
GSH ﬁndings would point on the systematic evaluation of
agents that may reduce oxidative stress early in the course of
illness. Additionally, the change in metabolic proﬁle in relation
toeachofthetreatmentsprovidedhasthepotentialtobeused
as a primary outcome measure. The extent to which the
change in any measure (or proﬁle of measures) is correlated
with improved short- or long-term outcomes would need to be
evaluated concurrently.
A major limitation of this study was the use of metabolite
ratios to Cr rather than absolute concentration. This makes
comparisons with some (particularly more recent) studies
more difﬁcult. In previous research, ratios to Cr have been
employed as a means to reduce subject-speciﬁc variations in
MRS data; recently, however, it has been suggested
60 that
this approach may be limited. Indeed some studies have
found signiﬁcant differences in absolute Cr levels for schizo-
phrenia,
60 bipolar disorder
13 and depression
61 within the
ACC/PFC as compared with healthy controls. On the other
hand, there are studies that have provided evidence of no
signiﬁcant differences in absolute Cr concentration within the
ACC of those with schizophrenia,
35,47,49 bipolar disorder
60,62
and depression.
54,56 The issues relating to Cr ratios are
vexed, however, by not determining absolute metabolite
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associated with ratio measurements. Equally, in this respect,
it should be borne in mind that no signiﬁcant difference in
LCModel-determined Cr concentration was detected across
all clusters.
Anotherlimitationofthisstudywasthepotentialinﬂuenceof
medication on spectroscopic ﬁndings. Although the distribu-
tion of medication exposure was relatively balanced across
the cluster groups, the potential effects of psychotropic
medications on each of these spectroscopic markers cannot
be ruled out. Although some studies
63,64 have found that
antipsychotic exposure is associated with reduced NAA
levels, there is conﬂicting evidence
35 that these medications
(as well as illness duration) have no direct effects on this
neurometabolite. In support of this, Bustillo et al.
65 found that
there were no further changes in NAA or glutamine (GLN)/
GLU within the ACC following 12 months of antipsychotic
treatment in a sample of young ‘minimally-treated’ schizo-
phrenia patients. However, this study did not account for the
potential effects of past substance use, and therefore the
impact of this cannot be ruled out. Further, our attempt to
comparetheneurometabolitelevelsofeachclustergroupwith
those of healthy controls may have been compromised by
subtle differences in age and years of education. Future
studies would beneﬁt by undertaking larger case–control and
longitudinal designs to explicate the apparent abnormalities in
the neurochemical markers revealed here.
Comparisonswith someoftheexistingliteratureare difﬁcult
owing to the differences in acquisition parameters as well as
hardware characteristics. This is particularly pertinent with
respect to GSH, which under ‘normal’ experimental settings is
difﬁcult to resolve even at 3T. The quality of the data in such a
setting is dependant on adequate signal to noise (SNR) ratio,
and to this end the effective shimming of the scanner. Most
reliably, GSH is resolved at 3T using a MEGAPRESS
acquisition sequence or quantum ﬁltering techniques, how-
ever, with adequate SNR, it is also possible to resolve GSH
using short TE-PRESS sequence with the appropriate use of
aGSHbasissetforanalysis.Inthecaseofour study,wewere
able to resolve GSH using an optimized TE¼35 PRESS
sequencewithallsubjectsincludedintheﬁnalanalysishaving
CRLBs of less than 20%. A similar argument also exists for
resolving GLU from GLN. Although we did not investigate
GLN in our study, we did reliably resolve GLU from GLN by
negating the need to report a combined ‘GLX’ metabolite.
Voxel size and placement can also differ substantially across
studies, and in some cases, large ‘prefrontal cortex’ voxels
can include the ACC (for example, see Taylor et al.
51). In
addition, the relative content of gray matter, white matter and
CSF within voxels across studies can also differ and as such
can have an inﬂuence on the ﬁnal metabolite concentration.
Although in our study, we segmented the ACC voxel, and
the results reported herein are those for gray matter only,
comparisons with other studies that have not similarly
corrected the acquisition voxel for gray matter content
become more difﬁcult.
If the ﬁeld of translational psychiatry is ever likely to make
realprogress, then there isanurgent need to moveaway from
poorly-validated diagnostic categories as the basis of evalu-
ating potential markers of underlying pathophysiologies. This
is particularly so when seeking to move clinical psychiatry
from a late to an early-intervention focus (which is currently
justiﬁed largely on the basis of reducing secondary psycho-
social impairment rather than changing illness trajectories
2).
This study presents evidence that neurometabolic proﬁles,
recorded by
1H-MRS, may have a much greater capacity to
differentiateyoungpeoplethantraditionalclinicalphenotypes,
and that such differences in proﬁles may lead to more speciﬁc
and targeted intervention studies.
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